

ECOP3

Under the Patronage of EU Commissioner Vytenis Andriukaitis

Thursday, 19 May 2016

10.30-12.00 Industry-sponsored Symposia

10.30-12.00 Industry-sponsored mini Symposia

12.15-13.45 Workshop for Spill Kit Training, Hand Washing & Disinfection, Usage of Clean Working Kit

12.15-13.45 Industry-sponsored Symposia

14.00	Opening Session		
14.30-15.00	Keynote – Lecture Team Medicine in Japan	Prof. Dr. Yuichiro Ohe	Tokyo, Japan
	EBM or Value-based Healthcare?		
	Chair	Marko Skelin	Sibenik, Croatia
15.00-15.30	Different Access and Prices of Oncology Treatments in Europe: Why?	Prof. Dr. Jaime Espin	Granada, Spain
15.30-16.00	Value based Pricing of oncological Drugs: Are we there yet?	Prof. Dr. Rok Hren	Ljubljana, Slovenia

16.00-16.30 Coffee Break

	Clinical Symposium: Off-label use & Challenges for future Market Access of high cost Drugs		
	Chair	Dr. Mikael Daouphars	Rouen, France
16.30-17:00	Safe Off-Label-Use in Oncology – which are the main Factors and what are the Challenges for Pharmacists?	Dr. Tilman Schöning	Heidelberg, Germany
17.00-17.30	Complexity & Challenges for Future Market Access of high cost Drugs - a Challenge for health and pharmaceutical Services	Dr. Chiara Poggiani	Verona, Italy
17.30-18.00	SROI (Social Return of Investment) - Analysis	Dr. Jose Ignacio Chacón & Dr. Ana Rosa Rubio Salvador	Toledo, Spain
18.00-18.30	Cancer Care in developing Countries: Does Africa needs monoclonal Antibodies? At what cost?	Sherif Kamal	Cairo, Egypt
	New Horizons Practical: Oncolytic Virus Therapy		
	Chair	Prof. Dr. Alain Astier	Creteil, France
16.30-17:00	Clinical Rationale	Dr. Karsten Geletneky	Darmstadt, Germany
17.00-17.30	Recommendations for Safe Use	Dr. Francois Lemare	Villejuif, France
	New Horizons Clinical: Drug Safety – Faking of Drugs and Security of manufactured Drugs		
	Chair	Bouchra Meddah	Rabat, Morocco
17.30-18.00	Faking of Drugs – Stakeholders’ Collaboration to protect Patients’ Health	Dr. Jana Mladá	Prague, Czech Republic
18.00-18.30	Falsified Medicines Directive – the current Position and Challenges for Hospital Pharmacists	Joan Peppard	Brussels, Belgium

18.30-21.00 Welcome Reception & Poster Presentation

Friday, 20 May 2016

08.00	Collaborative Care for the Benefit of Cancer Patients	Dr. Jan Smits	Brussels, Belgium
	Chair	Marika Saar	Tartu, Estonia
08.30-09.30	New Drugs of the Year	Jürgen Barth	Gießen, Germany
	Symposium Clinical: Oncology Patient in Community Pharmacy		
	Chair	Ahmet Bosnak	Gaziantep, Turkey
09.30-09.50	Clinical Pharmacist Interventions for oncology Outpatients	Fiona MacLean	Glasgow, UK
09.50-10.10	Medication Reconciliation	Dr. Christophe Bardin	Paris, France
10.10-10.30	Oral Chemotherapy: Are we following up Patients correctly on correct Administration and monitoring Adherence?	Dr. Fabrizio Festinese	Milan, Italy
10.30-10.50	A Cancer Patient in a Community Pharmacy	Dahna Arbanas	Karlovac, Croatia
	Proffed Papers - Mixed		
	Chair	Dr. Adrian Munilla Das	Alicante, Spain
09.30-11.00	P002 - EGFR Inhibition +/- Irradiation induce an HIF-2 Addiction in Head and Neck Cancer resistant Tumors P006 - Influence of SNP-SNP Combinations in Anthracycline Transporter Genes in the Standard Induction of Acute Myeloid Leukemia P010 - In Vitro and Ex Vivo of Temozolomide Resistance in GBM P029 - New Approaches for on-line Quality Control of Monoclonal Antibodies in Hospital Pharmacy. P035 - Identification of Raltitrexed photodegradation pathways in injectable solution.	Pierre Coliat Juan E. Megias Vericat Dr. Bodo Haas E. Jaccoulet Hassane Sadou Yaye	Strasbourg, France Valencia, Spain Bonn, Germany Paris, France Chatenay-Malabry, France
	International Relationships		
	Chair	Sherif Kamal	Cairo, Egypt
09.30-10.00	The New USP 800	Dr. Michael Koraleski	Omaha, USA
10.00-10.30	Drug Codex from Japan	Shinya Suzuki	Chiba, Japan
10.30-11.00	Guidelines in Germany	Dr. Ulrich Warnke	Nauen, Germany

11.00-11.30 Coffee Break

	Proffed Papers - Clinical		
	Chair	Marta Trojniak	Santorso, Italy
11.30-13.00	P011 - Genetic Variants in ERCC1, ERCC2 and SOD2 are associated with increased Risk of Neurotoxicity in Taxane-treated Breast Cancer Patients P055 - Patients' Satisfaction with Information on oral Anticancer Agents P074 - Supporting Adherence to oral Anticancer Agents: Clinical Practice and Clues to improve Care P098 - The Oncology Pharmacist as Part of the Palliative Treatment Team P110 - Surrogate Endpoints in metastatic Breast Cancer in First or Second Line Trials	Virginia Boso Christel Boons Lonneke Timmers Mirjam Crul Sandra Flores Moreno	Valencia, Spain Amsterdam, The Netherlands Amsterdam, The Netherlands Amsterdam, The Netherlands Sevilla, Spain

	Symposium Practical		
	Chair	Dr. Tilman Schöning	Heidelberg, Germany
11.30-12.15	Session on CAM	Prof. Dr. Hans-Peter Lipp	Tübingen, Germany
12.15-12.35	Nanoparticles for Drug Delivery in Cancer Treatment	Dr. Tanguy Boissenot	Paris, France
12.35-12.55	Nanomaterials as Destructive Sorbents for Surface Decontamination after Cytostatics Exposure	Dr. Václav Štengl	Husinec,-Rez, Czech Republic
	ESOP-Session		
	Chair	Klaus Meier	Soltau, Germany
11.30-12.00	Establishment of an European best-practice Model for Improvement of Health Care for oral Chemotherapy Patients – EPIC project	Andreja Eberl	Ljubljana, Slovenia
12.00-12.30	Results of MASHA Project (Research about Environmental Contamination by Cytotoxics and Management of Safe Handling Procedures).	Ewelina Korczowska	Poznan, Poland
12.30-13.00	Meet the ECOP-Board	Various Speakers	

13.00-14.30 Lunch Break

14.30-16.00 Industry-sponsored Symposia

14.30-16.00 Industry-sponsored Symposia

16.00-16.30 Coffee Break

	Interactive Clinical: Risk Management/ Medication Errors		
	Chair	Roman Goněc	Prague, Czech Republic
16.30-17.00	Riskmanagement – Overview	Michael Heymann	Siegen, Germany
17.00-17.30	Screening for Safety Signals of Tyrosine Kinase Inhibitors using Spontaneous Reporting Systems	Marin Banovac	London, UK
	Interactive Practical: How to interpret?		
	Chair	Shinya Suzuki	Chiba, Japan
16.30-17.15	- Pharmacoeconomic Studies Assessing the Cost-Effectiveness of Treatments for Metastatic Melanoma	Prof. John Cairns	London, UK
17.15-18.30	- Clinical Trials	Dr. Robert Separovic & Marko Skelin	Zagreb, Croatia Sibenik, Croatia
	Debate: This House believes in Centralized Compounding versus One-Stop-Shop for Patients which requires just-in-time Compounding on Site		
	Chair	Klaus Meier	Soltau, Germany
16.30-18.00	Pro – Robert Duncombe, UK & Shaun O’Connor, Australia Contra – Teresa Aqueveque, Chile & Stavroula Theophanus-Kitiri, Cyprus		

Saturday, 21 May 2016

	Chair		
08.30-09.00	Keynote – Lecture Demands Patients have to Oncology Pharmacists	Prof. Dr. Louis Denis	Antwerpen, Belgium
	What Doctors have to tell us?		

	Chair	Marika Saar	Tartu, Estonia
09.00-09.20	Medical Treatment for advanced Prostate Cancer	Prof. Dr. Hendrik van Poppel	Leuven, Belgium
09.20-09.40	Breast Cancer	Prof. Dr. Georgia Demetriou	Johannesburg, South Africa
09.40-10.00	Cardiovascular Effects and Cardiovascular Toxicity of Cancer Treatments	Dr. Ana Barac	Washington, USA
	Poster Discussion – Clinical		
	Chair	Andreja Eberl	Slovenia
10.00-11.30	<p>P008 - Relation between prostate-specific Antigen Levels and progression-free Survival in Patients with Prostate Cancer treated with Abiraterone Acetate</p> <p>P041 - Mobilisation of haematopoietic Stem Cells with Plerixafor on Patients with CD34<10 cells/mcL pre Apheresis</p> <p>P 042 - Follow-up Study: Drug Interactions in Chemotherapy Patients</p> <p>P044 - Contribution of Cetuximab in the Treatment of Nasopharyngeal Cancer: Experience of Algeria</p> <p>P045 - Improving Chemotherapy Relative Dose Intensity in localized Breast Cancer</p> <p>P085 - Evaluation of appropriate Glucarpidase Prescription to prevent iatrogenic Incident and reduce Medical Cost</p> <p>P113 - Fatal Interaction Between Brivudine And Capecitabine: A Case Report</p>	<p>Lucia Jimènez Pichardo</p> <p>Aitziber Lizardi</p> <p>H.C. van den Berg-Brouwer</p> <p>Kessal Réda</p> <p>Raul Diez Fernández</p> <p>C. Chauvin</p> <p>C. Garcia Yubero</p>	<p>Jerez de la Frontera, Spain</p> <p>San Sebastian, Spain</p> <p>Tilburg, The Netherlands</p> <p>Algiers, Algeria</p> <p>Madrid, Spain</p> <p>Nantes, France</p> <p>Madrid, Spain</p>
	Symposium Clinical: Immunotherapy		
	Chair	Prof. Dr. Vesna Pavlica	Zagreb, Croatia
10.00-10.30	Recent Developments and Research Topics in Immune Oncology	Prof. Dr. Damir Vrbanc	Zagreb, Croatia
10.30-11.00	Immunotherapy in Oncology – Side Effects and their Treatment	Prof. Dr. ZlatkoDembic	Oslo, Norway
11.00-11.30	Immunotherapy in Oncology - interdisciplinary Cooperation among Immunologist, Oncologist and Pharmacist	Dr. Irena Netikova Dr. Eva Závadová	Prague, Czech Republic

11.30-12.00 Coffee Break

	Interactive Clinical		
	Chair	Dr. Mirjam Crul	Amsterdam, The Netherlands
12.00-13.30	Multiprofessional Case Report Discussion	Robert Šeparović Marko Skelin Fiona MacLean Anita Margulis	Zagreb, Croatia Sibenik, Croatia Glasgow, UK Zurich, Switzerland
	Poster Discussion - Mixed		
	Chair	Dr. Tilman Schöning	Heidelberg, Germany
12.00-13.30	<p>P012 - A Strategy to screen and subsequently identify therapeutically valuable microRNAs that target a clinically established KITENIN Oncogene in Colorectal Cancer</p> <p>P021 - Toxicity Comparison between two commercial Presentations of Gemcitabine in recurrent superficial Bladder Cancer</p> <p>P028 - Comparative Evaluation of a Drug Website for Incompatibility: Stabilis, Trissel's Handbook and the currently available Tool in Japan</p> <p>P037 - Safety of antineoplastic Agents: the Main Issue in which E-Health Technologies could help to</p>	<p>So-Yean Park</p> <p>Rocio Gazquez Perez</p> <p>Shinya Suzuki</p> <p>Roberto Collado-Borrell</p>	<p>Sunchon, South Korea</p> <p>Spain</p> <p>Chiba, Japan</p> <p>Madrid, Spain</p>

	Pharmacotherapy Follow-up P040 - Preventing Medication Errors in Cancer Chemotherapy: Technology Contribution P051 - Educational Program for Patients on oral Chemotherapy: Challenge for Treatment Adherence and Quality of Life P096 - Nivolumab: the Concept of Dose Banding	Talens Amparo Nelly Etienne-Slloum Charlotte Ablard	Sant Joan, Spain Strasbourg, France Paris, France
13.30-14.00	Closing Session / Awards		